PMID: 15242256Jul 10, 2004Paper

AE-941 (AEterna)

Current Opinion in Investigational Drugs
Keith Dredge

Abstract

AEterna is developing AE-941, an angiogenesis inhibitor derived from the ultrafiltration of liquid shark cartilage, with matrix metalloprotease (MMP)-2, MMP-9 and vascular endothelial growth factor inhibitory properties, for the potential treatment of non-small-cell lung cancer.

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.